Entrada reports Q2 2026 results with DMD data due by year-end, VX-670 update aheadAug 5Quarterly updateEntrada Therapeutics, Inc.
Entrada registers Phase 2 long-term extension study for DMD exon skipping drugsJul 2Trial updateENTR-601-44ENTR-601-45
Sign inSign in